Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
JPMorgan Lifts Gold Price Forecast to $6,300 by End-2026 on Strong Central Bank and Investor Demand 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Japan’s Agricultural, Forestry and Fishery Exports Hit Record High in 2025 Despite Tariffs 
Gold and Asian Stocks Rebound as Market Volatility Eases and Global Sentiment Improves 
RBA Raises Interest Rates by 25 Basis Points as Inflation Pressures Persist 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
SK bioscience Co. will invest $1.79 billion by 2027 to expand its contract manufacturing capabilities to strengthen its readiness for the next pandemic, expand its overseas operations, and seize new business opportunities.
The proposed investment is twice the amount the company had spent in the past five years.
Of the total investment, t half would be spent on research and development (R&D) and the construction of a new R&D campus in Songdo, Incheon, which is expected to be completed in 2025.
SK bioscience has manufactured the COVID-19 vaccines of AstraZeneca and Novavax in South Korea under a partnership deal.
The company is seeking to ink deals with major pharmaceutical companies within the year, according to SK bioscience CEO Ahn Jae-yong.
"A deal could come as early as within the first half of this year," he said.
Also, the company has been looking for a possible merger deal in the United States in the field of cell and gene therapy.
The company swung to a deficit for the January-March period as waning demand led to a drop in the production of licensed COVID-19 vaccines. Its loss amounted to 29.2 billion won, compared with a profit of 23.8 billion won a year ago.
Ahn expected the company to make a turnaround in three years after investing aggressively in building up the foundations for future growth.
